Scilex Holding Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Scilex Holding Company (SCLX) on February 19, 2026. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of equity securities involving Oramed Pharmaceuticals Inc.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt levels. The primary financial details relate to a specific capital transaction:
- Warrant Issuance: 100,000 shares of common stock.
- Exercise Price: $20.00 per share.
- Expiration Date: December 13, 2029.
- Price Floor: $8.22 (subject to adjustments).
- Beneficial Ownership Limit: 4.99% (adjustable to 9.99% with notice).
Material Changes and Transaction Details
The Company entered into a Warrant Agreement with Oramed Pharmaceuticals Inc. to defer an amortization payment originally scheduled for October 1, 2025, under the "Tranche B Notes" issued in October 2024. In exchange for this deferral, the Company issued the new warrant. The filing notes that the deferred amortization payment was subsequently made to Oramed in November 2025. The warrant is immediately exercisable and was issued under Section 4(a)(2) and Rule 506(b) exemptions.
Outlook, Risks, and Contingencies
Registration Obligations: The Company must file a registration statement (Form S-3 or S-1) for the resale of shares underlying the warrant by March 31, 2026, or within 30 days of the agreement, whichever is later. If no registration statement is effective at the time of exercise, the warrant may be exercised on a cashless basis.
Corporate Events: The warrant includes provisions for fundamental transactions and changes of control. In the event of a specified change of control, the holder may force the Company to repurchase the warrant for cash equal to its Black-Scholes value.
Risks: The exercise price is subject to adjustment for stock splits, dividends, or subsequent offerings below the exercise price, subject to the $8.22 floor.
Key Facts for Investor Verification
- Verify the status of the Tranche B Notes and whether the November 2025 payment fully satisfied the deferred obligation.
- Confirm the dilution impact of the 100,000 warrant shares relative to the current outstanding share count.
- Monitor the filing of the required Form S-3 or S-1 registration statement by the March 31, 2026 deadline.
- Review the specific terms of the "fundamental transactions" clause to understand restrictions on future M&A activity.